Cargando…
When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework
BACKGROUND: Randomised controlled trials can provide evidence relevant to assessing the equity impact of an intervention, but such information is often poorly reported. We describe a conceptual framework to identify health equity-relevant randomised trials with the aim of improving the design and re...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623521/ https://www.ncbi.nlm.nih.gov/pubmed/28951402 http://dx.doi.org/10.1136/bmjopen-2016-015815 |
_version_ | 1783268107196825600 |
---|---|
author | Jull, J Whitehead, M Petticrew, M Kristjansson, E Gough, D Petkovic, J Volmink, J Weijer, C Taljaard, M Edwards, S Mbuagbaw, L Cookson, R McGowan, J Lyddiatt, A Boyer, Y Cuervo, L G Armstrong, R White, H Yoganathan, M Pantoja, T Shea, B Pottie, K Norheim, O Baird, S Robberstad, B Sommerfelt, H Asada, Y Wells, G Tugwell, P Welch, V |
author_facet | Jull, J Whitehead, M Petticrew, M Kristjansson, E Gough, D Petkovic, J Volmink, J Weijer, C Taljaard, M Edwards, S Mbuagbaw, L Cookson, R McGowan, J Lyddiatt, A Boyer, Y Cuervo, L G Armstrong, R White, H Yoganathan, M Pantoja, T Shea, B Pottie, K Norheim, O Baird, S Robberstad, B Sommerfelt, H Asada, Y Wells, G Tugwell, P Welch, V |
author_sort | Jull, J |
collection | PubMed |
description | BACKGROUND: Randomised controlled trials can provide evidence relevant to assessing the equity impact of an intervention, but such information is often poorly reported. We describe a conceptual framework to identify health equity-relevant randomised trials with the aim of improving the design and reporting of such trials. METHODS: An interdisciplinary and international research team engaged in an iterative consensus building process to develop and refine the conceptual framework via face-to-face meetings, teleconferences and email correspondence, including findings from a validation exercise whereby two independent reviewers used the emerging framework to classify a sample of randomised trials. RESULTS: A randomised trial can usefully be classified as ‘health equity relevant’ if it assesses the effects of an intervention on the health or its determinants of either individuals or a population who experience ill health due to disadvantage defined across one or more social determinants of health. Health equity-relevant randomised trials can either exclusively focus on a single population or collect data potentially useful for assessing differential effects of the intervention across multiple populations experiencing different levels or types of social disadvantage. Trials that are not classified as ‘health equity relevant’ may nevertheless provide information that is indirectly relevant to assessing equity impact, including information about individual level variation unrelated to social disadvantage and potentially useful in secondary modelling studies. CONCLUSION: The conceptual framework may be used to design and report randomised trials. The framework could also be used for other study designs to contribute to the evidence base for improved health equity. |
format | Online Article Text |
id | pubmed-5623521 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-56235212017-10-10 When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework Jull, J Whitehead, M Petticrew, M Kristjansson, E Gough, D Petkovic, J Volmink, J Weijer, C Taljaard, M Edwards, S Mbuagbaw, L Cookson, R McGowan, J Lyddiatt, A Boyer, Y Cuervo, L G Armstrong, R White, H Yoganathan, M Pantoja, T Shea, B Pottie, K Norheim, O Baird, S Robberstad, B Sommerfelt, H Asada, Y Wells, G Tugwell, P Welch, V BMJ Open Patient-Centred Medicine BACKGROUND: Randomised controlled trials can provide evidence relevant to assessing the equity impact of an intervention, but such information is often poorly reported. We describe a conceptual framework to identify health equity-relevant randomised trials with the aim of improving the design and reporting of such trials. METHODS: An interdisciplinary and international research team engaged in an iterative consensus building process to develop and refine the conceptual framework via face-to-face meetings, teleconferences and email correspondence, including findings from a validation exercise whereby two independent reviewers used the emerging framework to classify a sample of randomised trials. RESULTS: A randomised trial can usefully be classified as ‘health equity relevant’ if it assesses the effects of an intervention on the health or its determinants of either individuals or a population who experience ill health due to disadvantage defined across one or more social determinants of health. Health equity-relevant randomised trials can either exclusively focus on a single population or collect data potentially useful for assessing differential effects of the intervention across multiple populations experiencing different levels or types of social disadvantage. Trials that are not classified as ‘health equity relevant’ may nevertheless provide information that is indirectly relevant to assessing equity impact, including information about individual level variation unrelated to social disadvantage and potentially useful in secondary modelling studies. CONCLUSION: The conceptual framework may be used to design and report randomised trials. The framework could also be used for other study designs to contribute to the evidence base for improved health equity. BMJ Publishing Group 2017-09-25 /pmc/articles/PMC5623521/ /pubmed/28951402 http://dx.doi.org/10.1136/bmjopen-2016-015815 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Patient-Centred Medicine Jull, J Whitehead, M Petticrew, M Kristjansson, E Gough, D Petkovic, J Volmink, J Weijer, C Taljaard, M Edwards, S Mbuagbaw, L Cookson, R McGowan, J Lyddiatt, A Boyer, Y Cuervo, L G Armstrong, R White, H Yoganathan, M Pantoja, T Shea, B Pottie, K Norheim, O Baird, S Robberstad, B Sommerfelt, H Asada, Y Wells, G Tugwell, P Welch, V When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework |
title | When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework |
title_full | When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework |
title_fullStr | When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework |
title_full_unstemmed | When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework |
title_short | When is a randomised controlled trial health equity relevant? Development and validation of a conceptual framework |
title_sort | when is a randomised controlled trial health equity relevant? development and validation of a conceptual framework |
topic | Patient-Centred Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5623521/ https://www.ncbi.nlm.nih.gov/pubmed/28951402 http://dx.doi.org/10.1136/bmjopen-2016-015815 |
work_keys_str_mv | AT jullj whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT whiteheadm whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT petticrewm whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT kristjanssone whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT goughd whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT petkovicj whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT volminkj whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT weijerc whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT taljaardm whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT edwardss whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT mbuagbawl whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT cooksonr whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT mcgowanj whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT lyddiatta whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT boyery whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT cuervolg whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT armstrongr whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT whiteh whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT yoganathanm whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT pantojat whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT sheab whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT pottiek whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT norheimo whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT bairds whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT robberstadb whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT sommerfelth whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT asaday whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT wellsg whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT tugwellp whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework AT welchv whenisarandomisedcontrolledtrialhealthequityrelevantdevelopmentandvalidationofaconceptualframework |